**ABSTRACT**

**Background:** Besifovir dipivoxil maleate (BSV) with L-carnitine is the first-line antiviral agent for chronic hepatitis B (CHB) infection. We investigated whether BSV combined with L-carnitine improves hepatic steatosis (HS).

**Methods:** Treatment-naïve patients with CHB who were initiated on antiviral therapy (AVT) were enrolled. The magnitude of HS was assessed using hepatic steatosis index (HSI), and HS improvement was defined as a ≥ 10% reduction in the HSI score from the baseline.

**Results:** The mean age of the study patients was 56 years with a male predominance (n = 178, 64.7%). The mean body mass index (BMI), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and platelet count were 23.5 kg/m², 49.6 IU/L, 49.0 IU/L, and 191.3 × 10⁹/L, respectively. The mean HSI and fibrosis (FIB)-4 index were 32.6 and 0.5, respectively. After 6 months of AVT, platelet count (mean, 191.3→167.0 × 10⁹/L), fasting glucose (mean, 113.1→105.9 mg/dL), AST (mean, 49.6→28.0 IU/L), ALT (mean, 49.0→33.9 IU/L), and total cholesterol (mean, 170.0→162.1 mg/dL) levels significantly decreased (all \( P < 0.05 \)). In the BSV group, AST (mean, 95.2→30.2 IU/L) and ALT (mean, 81.1→31.1 IU/L) levels significantly reduced (all \( P < 0.05 \)), whereas HSI and FIB-4 index were maintained (all \( P > 0.05 \)). In the univariate analysis, age, BMI, diabetes, cirrhosis, fasting glucose level, and ALT were significantly associated with HS improvement (all \( P < 0.05 \)).

**Conclusion:** BSV with L-carnitine did not show any improvement of HS in patients with CHB. Further prospective randomized controlled studies are needed to validate the potential beneficial effects of BSV with L-carnitine in CHB infection.

**Keywords:** L-carnitine; Besifovir; Hepatic Steatosis; Entecavir; Tenofovir

---

**INTRODUCTION**

Chronic hepatitis B virus (HBV) infection is a public health problem affecting more than 400 million people worldwide.¹ If untreated, chronic hepatitis B (CHB) is likely to progress to advanced liver diseases, such as liver cirrhosis, hepatic decompensation and hepatocellular...
carcinoma (HCC), resulting in more than 600,000 deaths every year. Indeed, patients with HBV-related cirrhosis have a high risk of developing HCC, and its incidence rate is approximately up to 8% per year. Therefore, the primary therapeutic goal of CHB is to improve the long-term prognosis by preventing disease progression through potent viral suppression.

Accordingly, in the current international guidelines, nucleos(t)ide analogues with a high genetic barrier to resistance, such as entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF), are recommended as the first-line antiviral therapy (AVT). Especially in Korea, in addition to ETV, TDF, and TAF, besifovir dipivoxil maleate (BSV) with L-carnitine supplementation is also recommended as a first-line agent. BSV is a potent acyclic nucleoside phosphonate, which is converted into an active metabolite, a nucleos(t)ide analogue of guanosine monophosphate that inhibits HBV replication.

Recent clinical trials have shown that BSV with L-carnitine supplementation effectively suppresses HBV replication, and that the antiviral efficacy and safety of BSV are comparable to those of TDF.

Approximately, 14%-70% of cases, hepatic steatosis (HS) was noted among patients with CHB. Controversial interaction between HS and CHB has been reported. Some studies have shown that CHB is not a protective factor against fatty liver. Another Asian study has demonstrated that the level of hepatitis B surface antigen (HBsAg) in the liver decreased as the severity of HS worsened. In contrast, an unfavorable impact of HS in patients with CHB includes the facilitation of progression to advanced liver disease. Moreover, a recent study has shown that the presence of metabolic syndrome is closely associated with HS, and is an independent risk factor for cirrhosis and HCC among patients with CHB. All these signify that assessment and management of co-existing HS in patients with CHB are important.

L-carnitine (L-beta-hydroxy-g-N-trimethylaminobutyric acid), used in combination with BSV, is an essential nutrient that promotes the migration of long-chain fatty acids and converts fat into mitochondrial energy. Administration of L-carnitine improves or prevents hepatic damage with various causes. Carnitine reduces intrahepatic lipid accumulation, increases the expression of metabolic products associated with β-oxidation, and significantly reduces fatty acid levels in the liver. Carnitine also ameliorates the inflammation caused by non-alcoholic fatty liver disease (NAFLD). Furthermore, carnitine and vitamin complex supplementation reduce the serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin in patients with NAFLD. In a clinical study, BSV reduced the serum L-carnitine level in 94.1% of 114 patients, and the level normalized after taking L-carnitine supplements.

Thus, we investigated whether BSV combined with L-carnitine could improve HS when compared to ETV and TDF, and identified the independent predictors of improvement of HS in patients with CHB.

**METHODS**

**Study participants**

Between November 2017 and October 2018, 617 treatment-naïve patients with CHB who were initiated on AVT at Severance Hospital, Yonsei University College of Medicine (Seoul, Korea) were considered eligible for this retrospective cohort study. CHB was defined as the persistent...
presence of serum HBV surface antigen (HBsAg) for at least 6 months. The exclusion criteria were as follows; 1) patients who were initiated on AVT except BSV, ETV, and TDF, 2) HCC at enrollment or any such previous history, 3) decompensated liver disease at enrollment or any such previous history, 4) liver transplanted status at enrollment or any such past medical history, 5) insufficient laboratory information, 6) treatment duration ≤ 6 months, 7) use of medication potentially associated with fatty liver, 8) history of any other malignancy.

Enrollment and follow-up
AVT was administered according to the treatment guidelines of the Korean Association for the Study of the Liver and the reimbursement guidelines of the National Health Insurance Service of Korea. After AVT initiation, each patient was followed up after 3–6 months and underwent laboratory tests and ultrasonographic evaluation.

Estimation of HS and liver fibrosis
In addition to ultrasonographic assessment, the magnitude of HS was assessed using hepatic steatosis index (HSI). The equation used for the calculation of HSI is as follows: HSI = 8 × ALT / AST + BMI + 2, if diabetes mellitus is present; + 2, if the patient is female; values ≥ 36 suggest fatty liver. In this study, the HS improvement was defined as ≥ 10% reduction in HSI from the baseline. The HSI formula was developed based on a logistic regression model, in a retrospective cohort study that excluded patients with chronic liver diseases including CHB infection. However, HSI has acceptable diagnostic accuracy for both patients with CHB and the general population (area under the receiver operating characteristic curve, 0.65–0.79). These findings support the use of HSI to assess the degree of fatty liver in patients with CHB. Besides, the degree of hepatic fibrosis was identified using the fibrosis-4 index (FIB-4 index). The equation used for the calculation of FIB-4 index is as follows: FIB-4 index = (Age × AST) / (PLT × √ALT).

Statistical analyses
All statistical analyses were conducted using IBM SPSS software, version 25.0 (SPSS Inc. Chicago, IL, USA) for Windows. The continuous variables were expressed as the mean ± standard deviation (SD), and the categorical variables were presented as frequencies with percentages. To examine the differences between the two groups, the continuous variables were compared using Student’s t-test or Mann-Whitney U test and the categorical variables were compared using χ² test or Fisher’s exact test. Changes in variables between baseline and follow-up were analyzed by paired t-test. The variables that were statistically significant in the univariate analysis were added to a multiple logistic regression model to identify the independent predictors of HS improvement from the baseline. Statistical significance was considered for comparisons with a two-tailed P-value of < 0.05.

A sample size of 275 (24 in the BSV group and 251 in the ETV or TDF group) achieved 93% power to detect a between group-difference of 0.25, at a significance level of 0.05. In the initial analysis, we assumed the rate of significant reduction in HSI in the control group (ETV or TDF) would be around 0%, so we set the proportion of reduction in HSI in the control group as 0.05. The proportion of reduction in HSI in BSV group was assumed to be 0.05 under the null hypothesis and 0.30 under the alternative hypothesis.

Ethics statement
The study was approved by the Institutional Review Board (IRB) of Severance Hospital, Yonsei University Health System (IRB 4-2020-0034) and was performed according to the
ethical guidelines of the 1975 Helsinki declaration. The requirement of informed consent was waived due to the retrospective nature of this study.

RESULTS

Baseline characteristics
Among the 617 treatment-naïve patients with CHB who started AVT between November 2017 and October 2018, 588 patients who started AVT consisting of BSV, ETV, or TDF were considered. After excluding 313 patients according to the exclusion criteria, 275 patients were finally selected for the statistical analysis (Fig. 1). The baseline characteristics of the study population are described in Table 1. The mean age was 56 years, with a male predominance (n = 178, 64.7%). Diabetes, hypertension, and liver cirrhosis were identified in 31 (11.3%), 57 (20.7%), and 82 (29.8%) patients, respectively. The mean BMI, AST, ALT, and platelet count were 23.5 kg/m², 49.6 IU/L, 49.0 IU/L, and 191.3 × 10⁹/L, respectively. The mean HSI and FIB-4 index were 32.6 and 0.5, respectively. While fatty liver was identified in 14 (5.1%) patients based on the ultrasonographic evaluation, it was diagnosed in 66 (23.6%) patients by HSI.

Comparison between patients with BSV and those with ETV or TDF
Of the study population, only 24 (8.7%) patients started AVT consisting of BSV with L-carnitine, whereas the other 251 (91.3%) started with ETV (n = 154, 56.0%) or TDF (n = 97, 35.3%). The patients in the BSV group were significantly younger (mean, 48.6 vs. 56.7 years), and had lower fasting glucose level (mean, 99.4 vs. 114.4 mg/dL), higher AST level (mean, 95.2 vs. 45.2 IU/L), higher ALT level (mean, 81.1 vs. 45.9 IU/L), and higher total cholesterol level (mean, 185.6 vs. 167.0 mg/dL) (all \( P < 0.05 \)) than those in the ETV/TDF group (Table 1). The proportion of patients with fatty liver diagnosed by ultrasonography was higher in the BSV group than those in the ETV/TDF group (12.5% vs. 4.4%, \( P = 0.084 \)). When HSI was used
to define HS, the proportion of patients with fatty liver was higher in the BSV group than those in the ETV/TDF group (n = 11 [45.8%] vs. n = 55 [21.9%]; P = 0.998) (Table 1).

When patients in the BSV group were compared to those in the ETV or TDF group, respectively, similar findings were observed, except similar fasting glucose level (Supplementary Table 1).

Changes in the laboratory variables, HSI, and FIB-4 index after 6 months of AVT

After 6 months of AVT, platelet count (mean, 191.3 → 167.0 × 10⁹/L), fasting glucose (mean, 113.1 → 105.9 mg/dL), AST (mean, 49.6 → 28.0 IU/L), ALT (mean, 49.0 → 33.9 IU/L), and total cholesterol (mean, 170.0 → 162.1 mg/dL) levels were significantly decreased (all P < 0.05) (Table 2). The HSI significantly decreased (mean, 32.6 → 31.4; P < 0.001), whereas the FIB-4 index significantly increased (mean, 0.5 → 0.6; P < 0.001) after 6 months of AVT.

Among the patients in the BSV group, AST (mean, 95.2 → 30.2 IU/L), and ALT (mean, 81.1 → 31.1 IU/L) levels significantly decreased (all P < 0.05), whereas HSI and FIB-4 index were

| Table 1. Baseline characteristics of the study population (n = 275) |
|-------------------------------------------------|
| **Variables**                                  | **Total (n = 275)** | **Besifovir with L-carnitine (n = 24, 8.7%)** | **Entecavir or tenofovir (n = 251, 91.3%)** | **P value** |
| **Demographic parameters**                     |                    |                                              |                                              |            |
| Age, yr                                        | 56.0 ± 12.2        | 48.6 ± 10.8                                 | 56.7 ± 12.1                                 | 0.002      |
| Sex, male                                      | 178 (64.7%)        | 15 (62.5%)                                  | 163 (64.9%)                                 | 0.811      |
| Body mass index, kg/m²                         | 23.5 ± 3.6         | 24.3 ± 3.3                                  | 23.5 ± 3.6                                  | 0.301      |
| Diabetes                                       | 31 (11.3%)         | 0 (0)                                       | 31 (12.4%)                                  | 0.068      |
| Hypertension                                   | 57 (20.7%)         | 2 (8.3%)                                    | 55 (21.9%)                                  | 0.117      |
| Cirrhosis                                      | 82 (29.8%)         | 10 (41.7%)                                  | 72 (28.7%)                                  | 0.184      |
| **Fatty liver diagnosed by ultrasonography**   | 14 (5.1%)          | 3 (12.5%)                                   | 11 (4.4%)                                   | 0.084      |
| **Laboratory parameters**                      |                    |                                              |                                              |            |
| Platelet count, 10⁹/L                          | 191.3 ± 76.5       | 183.9 ± 60.8                                | 192.0 ± 77.9                                | 0.923      |
| Fasting glucose, mg/dL                         | 113.0 ± 37.3       | 99.4 ± 13.8                                 | 114.4 ± 38.6                                | < 0.001    |
| Aspartate aminotransferase, IU/L               | 49.0 ± 58.3        | 81.1 ± 50.3                                 | 45.9 ± 58.2                                 | 0.005      |
| Alanine aminotransferase, IU/L                 | 49.6 ± 64.2        | 95.2 ± 73.3                                 | 45.2 ± 61.6                                 | < 0.001    |
| Total bilirubin, mg/dL                         | 0.8 ± 0.4          | 0.8 ± 0.3                                   | 0.8 ± 0.5                                   | 0.934      |
| Serum albumin, g/dL                            | 4.1 ± 0.5          | 4.2 ± 0.3                                   | 4.1 ± 0.5                                   | 0.096      |
| Serum creatinine, mg/dL                        | 0.8 ± 0.3          | 0.8 ± 0.3                                   | 0.8 ± 0.3                                   | 0.705      |
| Total cholesterol, mg/dL                       | 168.4 ± 40.3       | 185.6 ± 31.8                                | 167.0 ± 40.7                                | 0.030      |
| Hepatic steatosis index                        | 32.6 ± 5.4         | 35.8 ± 7.1                                  | 32.3 ± 5.1                                  | 0.002      |
| FIB-4 index                                    | 0.5 ± 0.4          | 0.5 ± 0.6                                   | 0.5 ± 0.4                                   | 0.905      |

Variables are expressed as mean ± standard deviation or number (%).

| Table 2. Changes in laboratory parameters, hepatic steatosis index, and fibrosis-4 index after 6 months of antiviral therapy |
|---------------------------------------------------------------------------------------------------------------------|
| **Variables**                                                              | **Entire population** | **Besifovir with L-carnitine** | **Entecavir or tenofovir** |
| **Laboratory parameters**                                                  | Baseline At 6 months | P value | Baseline At 6 months | P value | Baseline At 6 months | P value |
| Platelet count, 10⁹/L                                                       | 191.3 ± 76.5         | 167.0 ± 67.0 | < 0.001 | 183.9 ± 60.8 | 182.8 ± 67.9 | 0.792 | 192.0 ± 77.9 | 165.5 ± 70.1 | < 0.001 |
| Fasting glucose, mg/dL                                                      | 113.1 ± 37.4         | 105.9 ± 27.5 | 0.001 | 99.4 ± 13.8 | 96.5 ± 9.5 | 0.279 | 114.4 ± 38.6 | 106.8 ± 28.5 | 0.001 |
| Aspartate aminotransferase, IU/L                                           | 49.0 ± 58.3          | 33.9 ± 25.6 | < 0.001 | 81.1 ± 50.3 | 31.1 ± 21.3 | < 0.001 | 45.9 ± 58.2 | 34.1 ± 26.0 | 0.002 |
| Alanine aminotransferase, IU/L                                             | 49.6 ± 64.2          | 28.0 ± 17.9 | < 0.001 | 95.2 ± 73.3 | 30.2 ± 13.1 | < 0.001 | 45.2 ± 61.6 | 27.8 ± 18.3 | < 0.001 |
| Total bilirubin, mg/dL                                                     | 0.8 ± 0.4            | 0.8 ± 0.7 | 0.396 | 0.8 ± 0.3 | 0.8 ± 0.4 | 0.751 | 0.8 ± 0.5 | 0.8 ± 0.7 | 0.363 |
| Serum albumin, g/dL                                                        | 4.1 ± 0.5            | 4.1 ± 0.3 | 0.391 | 4.2 ± 0.3 | 4.3 ± 0.4 | 0.571 | 4.1 ± 0.5 | 4.1 ± 0.5 | 0.450 |
| Serum creatinine, mg/dL                                                    | 0.8 ± 0.3            | 0.8 ± 0.3 | 0.235 | 0.8 ± 0.1 | 0.8 ± 0.2 | 0.579 | 0.8 ± 0.3 | 0.8 ± 0.3 | 0.200 |
| Total cholesterol, mg/dL                                                   | 170.0 ± 40.0         | 162.1 ± 38.2 | 0.002 | 185.6 ± 31.8 | 192.7 ± 32.0 | 0.194 | 168.4 ± 40.5 | 158.8 ± 37.4 | < 0.001 |
| Hepatic steatosis index                                                    | 32.6 ± 5.4           | 31.4 ± 4.9 | < 0.001 | 35.8 ± 7.1 | 33.7 ± 5.3 | 0.118 | 32.3 ± 5.1 | 31.2 ± 4.8 | < 0.001 |
| Fibrosis-4 index                                                           | 0.5 ± 0.4            | 0.6 ± 0.6 | < 0.001 | 0.5 ± 0.6 | 0.4 ± 0.6 | 0.758 | 0.5 ± 0.4 | 0.6 ± 0.6 | < 0.001 |

Variables are expressed as mean ± standard deviation.
maintained (all $P > 0.05$) (Table 2). Among patients in the ETV/TDF group, platelet count, fasting glucose, AST and ALT levels, total cholesterol, HSI, and FIB-4 index were significantly changed (all $P < 0.05$) (Table 2). The respective changes in the laboratory parameters, HSI, and FIB-4 index according to ETV and TDF are enumerated in Supplementary Table 2. The changes in HSI according to the antiviral agents are depicted in Fig. 2.

**Independent predictors of treatment outcomes**

Univariate and subsequent multivariate analyses were performed to identify the independent predictors of improvement of HS (Table 3). In the univariate analysis, age, BMI, diabetes, cirrhosis, fasting glucose level, and ALT level were significantly associated with improvement of HS (all $P < 0.05$). In the subsequent multivariate analysis, lower BMI (odds ratio [OR], 0.816; 95% confidence interval [CI], 0.727–0.917; $P = 0.001$), diabetes (OR, 3.272; 95% CI, 1.089–9.825; $P = 0.035$), absence of cirrhosis (OR, 0.351; 95% CI, 0.135–0.909; $P = 0.031$), higher fasting glucose level (OR, 1.013; 95% CI, 1.002–1.025; $P = 0.019$), higher ALT level (OR, 1.040; 95% CI, 1.023–1.064; $P < 0.001$) were significantly associated with the higher probability of HS improvement after 6 months of AVT. However, BSV with L-carnitine supplementation as compared to ETV or TDF was not associated with the probability of HS improvement ($P = 0.415$).

When 66 (23.6%) patients with fatty liver based on HSI > 36 at baseline, who might benefit from HS improvement, were selected for a subgroup analysis, only higher ALT level (OR, 1.214; 95% CI, 1.017–1.449; $P = 0.032$) was independently associated with the higher probability of HS improvement (Table 4). When 8 patients with fatty liver diagnosed by
ultrasonography were further added \( (n = 74, 26.9\% \text{ in total}) \), only higher ALT level (OR, 1.228; 95% CI, 1.025–1.470; \( P = 0.026 \)) was independently associated with the higher probability of HS improvement (Supplementary Table 3).

### DISCUSSION

Current Korean guidelines for the treatment of CHB recommend BSV as a first-line AVT agent, together with ETV, TDF, and TAF.\(^4\) However, a recent clinical study showed that BSV reduced the serum L-carnitine level in 94.1% of 114 patients, although the level normalized

---

**Table 3.** Binary logistic regression to identify predictors of improvement of hepatic steatosis (≥ 10% reduction in hepatic steatosis index from the baseline) after 6 months of antiviral therapy

| Variables | Univariate | | Multivariate | |
|-----------|------------|----------------|---------------|----------------|
|           | OR \( P \) value | OR \( 95\% \) CI | \( P \) value | |

**Demographic parameters**

| Age, yr            | 0.988 (0.026) | 0.937 (0.963–1.031) | 0.852 |
|--------------------|---------------|----------------------|-------|
| Sex, male          | 1.668 (0.244) | -                    | -     |
| Body mass index, kg/m\(^2\) | 0.837 (0.001) | 0.816 (0.727–0.917) | 0.001 |
| Diabetes           | 4.376 (0.001) | 3.272 (1.089–9.825) | 0.035 |
| Hypertension       | 1.199 (0.974) | -                    | -     |
| Cirrhosis          | 0.392 (0.005) | 0.351 (0.133–0.909) | 0.031 |

**Fatty liver diagnosed by ultrasonography**

| 1.849 (0.732) | - | - | - |

**Laboratory parameters**

| Platelet count, \(10^9/L\) | 1.002 (0.182) | - | - | - |
| Fasting glucose, mg/dL | 1.012 (0.001) | 1.013 (1.002–1.025) | 0.019 |
| Aspartate aminotransferase, IU/L | 0.983 (0.086) | - | - | - |
| Alanine aminotransferase, IU/L | 1.020 (0.001) | 1.043 (1.023–1.064) | < 0.001 |
| Total bilirubin, mg/dL | 0.909 (0.906) | - | - | - |
| Serum albumin, g/dL | 1.489 (0.736) | - | - | - |
| Serum creatinine, mg/dL | 0.434 (0.249) | - | - | - |
| Total cholesterol, mg/dL | 0.586 (0.757) | - | - | - |
| Besifovir with L-carnitine (vs. entecavir or tenofovir) | 0.709 (0.415) | - | - | - |

**Table 4.** Binary logistic regression to identify predictors of the improvement of hepatic steatosis after 6 months of antiviral therapy among the patients with fatty liver based on HSI \( > 36 \)

| Variables | Univariate | | Multivariate | |
|-----------|------------|----------------|---------------|----------------|
|           | OR \( P \) value | OR \( 95\% \) CI | \( P \) value | |

**Demographic parameters**

| Age, yr            | 1.204 (0.672) | - | - | - |
|--------------------|---------------|----------------|---------------|----------------|
| Sex, male          | 1.237 (0.720) | - | - | - |
| Body mass index, kg/m\(^2\) | 0.781 (< 0.001) | 0.670 (0.424–1.061) | 0.088 |
| Diabetes           | 6.378 (0.292) | - | - | - |
| Hypertension       | 0.433 (0.912) | - | - | - |
| Cirrhosis          | 0.045 (0.030) | 0.003 (0.000–7.570) | 0.146 |

**Fatty liver diagnosed by ultrasonography**

| 2.856 (0.810) | - | - | - |

**Laboratory parameters**

| Platelet count, \(10^9/L\) | 1.006 (0.228) | - | - | - |
| Fasting glucose, mg/dL | 1.020 (0.174) | - | - | - |
| Aspartate aminotransferase, IU/L | 0.810 (0.058) | - | - | - |
| Alanine aminotransferase, IU/L | 1.166 (0.002) | 1.214 (1.017–1.449) | 0.032 |
| Total bilirubin, mg/dL | 1.147 (0.892) | - | - | - |
| Serum albumin, g/dL | 0.604 (0.491) | - | - | - |
| Serum creatinine, mg/dL | 0.030 (0.017) | 0.000 (0.000–3.219) | 0.066 |
| Total cholesterol, mg/dL | 0.994 (0.650) | - | - | - |
| Besifovir with L-carnitine (vs. entecavir or tenofovir) | 33.209 (0.986) | - | - | - |

Improvement of hepatic steatosis was defined as a ≥ 10% reduction in the HSI score from the baseline.

HSI = hepatic steatosis index, OR = odds ratio, CI = confidence interval.
after taking L-carnitine supplements. Thus, carnitine supplementation was routinely applied to all patients taking BSV. In living cells, L-carnitine transports fatty acids from the cytosol into the mitochondria during the breakdown of lipids, for the generation of energy. Moreover, carnitine administration prevents hepatic damage by reducing intrahepatic fat accumulation and inflammation. Because L-carnitine is an essential nutrient involved in fatty-acid metabolism that protects the liver, we hypothesized that L-carnitine plus BSV would affect the hepatic fat burden in patients with CHB.

During the 6 months follow-up period, univariate and subsequent multivariate analyses found that BSV with L-carnitine supplementation did not show a significant reduction in the amount of hepatic fat estimated by HSI as compared to that with ETV or TDF. In the subgroup of patients with fatty liver (HSI > 36) or those with fatty liver diagnosed by ultrasonography or HSI > 36, BSV with L-carnitine supplementation was not significantly associated with an improvement in HS.

Our study has several strengths. First, to the best of our knowledge, despite the negative results, this is the first study to investigate the potential effects of BSV and L-carnitine on fatty liver. To date, L-carnitine has been known to be effective for improving fatty liver. However, because the primary aim of L-carnitine supplementation is to compensate for L-carnitine deficit caused by BSV, our clinical setting was different from those of the other previous studies, which supports the clinical implication of our current study.

Second, we investigated the effects of BSV and L-carnitine on fatty liver using the control group of patients treated with ETV and TDF, which were previously administered as the first line agents. In contrast to the BSV group, ETV and TDF group showed a decline in the platelet count and an increment in FIB-4 index, which is an unexpected phenomenon with AVT using high-potent antiviral agents. In addition, baseline AST and ALT levels, which are the key factors for calculating HSI and FIB-4 index, were significantly different between the BSV and ETV/TDF groups. This might be a reason for the potential false negative results in the BSV group. Therefore, well-designed prospective randomized trials with a large sample size are required.

Third, we tried to find independent predictors for HS improvement. Higher BMI and presence of cirrhosis were independently associated with the lower probability of HS improvement. The exact reason for this phenomenon is not clear. Among the various mechanisms associated with HS development, obesity is a major associated risk factor. Thus, the result of this study can be partly explained by the fact that L-carnitine supplementation might not be sufficient to improve HS when the fat burden outside the liver is high. In addition, cirrhosis with structural and functional abnormality might be associated with poor response to L-carnitine and poor mobilization of hepatic fat. However, further validation studies are required to elucidate these assumptions. In another study, patients with non-alcoholic steatohepatitis (NASH) were found to be at increased risk for liver fibrosis, cirrhosis, and HCC. Patients with lower BMI and without diabetes or cirrhosis showed improvement in HS. Because fasting glucose or ALT levels are associated with diabetes or cirrhosis, an improvement in HS is found with low glucose or ALT levels.

This study had several limitations. First, the size of the BSV and ETV/TDF groups differed significantly (n = 24 vs. 251). This may have hampered detection of a beneficial effect, as indicated by the non-significantly higher mean reduction in HSI in the BSV group (35.8 to 33.7) versus the ETV/TDF group (32.3 to 31.2). Moreover, the follow-up treatment period (6 months)
may have been insufficient to fully determine the effect of L-carnitine on fatty liver. Therefore, larger-scale long-term clinical studies are needed to confirm the effects of BSV with L-carnitine on fatty liver in patients with CHB. Second, although recent studies partially support the use of HSI to assess the degree of fatty liver in patients with CHB, no evidence is available on whether HSI is appropriate for patients with CHB, especially those with elevated liver enzyme levels who require antiviral therapy. In addition, the clinical implications of a reduction in the HSI score of >10% from the baseline are unclear. Furthermore, because only 10 patients underwent paired transient elastography, our results could not be reproduced with controlled attenuation parameters. Also, because this was a retrospective study, we were unable to analyze the serum L-carnitine level. Thus, unfortunately, we cannot confirm that our findings are due to the effect of L-carnitine. In further studies, changes in histological status should be assessed, or more reliable noninvasive surrogates and assessment of the serum carnitine level during BSV treatment should be implemented. Third, as this was a retrospective study performed in a single tertiary academic institute, the results might not be applicable to the general population. Indeed, the proportion of patients diagnosed with fatty liver was only 5.1%, lower than the prevalence rate of fatty liver in Korea (26%–40%). Similarly, the proportion of patients with HSI-based fatty liver was 23.6%, lower than the prevalence rate of HSI-based fatty liver in Korea (64.3%). Finally, the frequency of a significant improvement in HSI was unexpectedly high in the control group (ETV or TDF treatment), which may explain the potential false-negative results in the BSV group. The reduction in total cholesterol level in patients on ETV or TDF (mean, 168.4 → 158.8 mg/dL) was greater than that in those on BSV (mean, 185.6 → 192.7 mg/dL), which might explain the significant reduction in HSI in the ETV and TDF groups. However, further randomized prospective studies including large populations are needed to confirm this finding.

In conclusion, BSV and L-carnitine did not show improvement of HS in patients with CHB receiving BSV combined with L-carnitine supplementation. However, further prospective randomized controlled trials are required to elucidate the potential beneficial effects of BSV with L-carnitine supplementation in patients with CHB.

SUPPLEMENTARY MATERIALS

Supplementary Table 1
Baseline characteristics of the study population according to the antiviral agents

Click here to view

Supplementary Table 2
Changes in laboratory parameters, hepatic steatosis index, and fibrosis-4 index after 6 months of entecavir and tenofovir treatment

Click here to view

Supplementary Table 3
Binary logistic regression to identify predictors of the improvement of hepatic steatosis after 6 months of antiviral therapy among the patients with fatty liver (diagnosed by ultrasonography or based on HSI > 36)

Click here to view
REFERENCES

1. Lai CL, Yuen MF. Chronic hepatitis B--new goals, new treatment. *N Engl J Med* 2008;359(23):2488-91.  
PUBMED | CROSSREF

2. Yuen MF, Lai CL. Treatment of chronic hepatitis B. *Lancet Infect Dis* 2001;1(4):232-41.  
PUBMED | CROSSREF

3. Fattovich G, Str satisfi lini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. *Gastroenterology* 2004;127(5 Suppl 1):S35-50.  
PUBMED | CROSSREF

4. Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B. *Clin Mol Hepatol* 2019;25(2):93-159.  
PUBMED | CROSSREF

5. Brown RS Jr, McMahon BJ, Lok AS, Wong JB, Ahmed AT, Mouchil MA, et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: a systematic review and meta-analysis. *Hepatology* 2016;63(1):319-33.  
PUBMED | CROSSREF

6. Lampertico P, Agarwal K, Berg T, Buti M, Janssen HL, Papatheodoridis G, et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. *J Hepatol* 2017;67(2):370-98.  
PUBMED | CROSSREF

7. Lai CL, Ahn SH, Lee KS, Um SH, Cho M, Yoon SK, et al. Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. *Gut* 2014;63(6):996-1004.  
PUBMED | CROSSREF

8. Yuen MF, Lee SH, Kang HM, Kim CR, Kim J, Ngai V, et al. Pharmacokinetics of LB80331 and LB80317 following oral administration of LB80380, a new antiviral agent for chronic hepatitis B (CHB), in healthy adult subjects, CHB patients, and mice. *Antimicrob Agents Chemother* 2009;53(5):1779-85.  
PUBMED | CROSSREF

9. Yuen MF, Kim J, Kim CR, Ngai V, Yuen JC, Min C, et al. A randomized placebo-controlled, dose-finding study of oral LB80380 in HBsAg-positive patients with chronic hepatitis B. *Antivir Ther* 2006;11(8):977-83.  
PUBMED

10. Yuen MF, Han KH, Um SH, Yoon SK, Kim HR, Kim J, et al. Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease. *Hepatology* 2010;51(3):767-76.  
PUBMED | CROSSREF

11. Yuen MF, Ahn SH, Lee KS, Um SH, Cho M, Yoon SK, et al. Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: results from a multicentre study. *J Hepatol* 2015;62(2):526-32.  
PUBMED | CROSSREF

12. Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. *J Hepatol* 2017;67(4):862-73.  
PUBMED | CROSSREF

13. Kim DS, Jeon MY, Lee HW, et al. Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir. *Clin Mol Hepatol* 2019;25(3):283-93.  
PUBMED | CROSSREF

14. Wang B, Li W, Fang H, Zhou H. Hepatitis B virus infection is not associated with fatty liver disease: Evidence from a cohort study and functional analysis. *Med Mol Rep* 2019;19(1):320-6.  
PUBMED

15. Wang MM, Wang GS, Shen F, Chen GY, Pan Q, Fan JG. Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors. *Dig Dis Sci* 2014;59(10):2571-9.  
PUBMED | CROSSREF

16. Seto WK, Hui RW, Mak LY, Fung J, Cheung KS, Liu KS, et al. Association between hepatic steatosis, measured by controlled attenuation parameter, and fibrosis burden in chronic hepatitis B. *Clin Gastroenterol Hepatol* 2018;16(4):575-583.e2.  
PUBMED | CROSSREF

17. Cheng JY, Wong VW, Tse YK, Chim AM, Chan HL, Wong GL. Metabolic syndrome increases cardiovascular events but not hepatic events and death in patients with chronic hepatitis B. *Hepatology* 2016;64(5):1507-17.  
PUBMED | CROSSREF

18. Chon YE, Kim KJ, Jung KS, Kim SU, Park JY, Kim Y, et al. The relationship between type 2 diabetes mellitus and non-alcoholic fatty liver disease measured by controlled attenuation parameter. *Yonsei Med J* 2016;57(4):885-92.  
PUBMED | CROSSREF
19. Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, Yiu KK, et al. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut 2009;58(1):111-7.

20. Ishikawa H, Takaki A, Tsuzaki R, Yasunaka T, Koike K, Shimomura Y, et al. L-carnitine prevents progression of non-alcoholic steatohepatitis in a mouse model with upregulation of mitochondrial pathway. PLoS One 2014;9(7):e100627.

21. Fujisawa K, Takami T, Matsuzaki A, Matsumoto T, Yamamoto N, Terai S, et al. Evaluation of the effects of L-carnitine on medaka (Oryzias latipes) fatty liver. Sci Rep 2017;7(1):2749.

22. Jun DW, Kim BI, Cho YK, Kim HJ, Kwon YO, Park SY, et al. Efficacy and safety of entecavir plus carnitine complex (GODEX®) compared to entecavir monotherapy in patient with ALT elevated chronic hepatitis B: randomized, multicenter open-label trials. The GOAL study. Clin Mol Hepatol 2013;19(2):165-72.

23. Lee JH, Kim D, Kim HJ, Lee CH, Yang JJ, Kim W, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis 2010;42(7):503-8.

24. Zhang Z, Wang G, Kang K, Wu G, Wang P. Diagnostic accuracy and clinical utility of a new noninvasive index for hepatic steatosis in patients with hepatitis B virus infection. Sci Rep 2016;6(1):32875.

25. Kahl S, Straßburger K, Nowotny B, Livingstone R, Klüppelholz B, Keßel K, et al. Comparison of liver fat indices for the diagnosis of hepatic steatosis and insulin resistance. PLoS One 2014;9(4):e94059.

26. Nishikawa H, Nishijima N, Enomoto H, Sakamoto A, Nasu A, Komekado H, et al. Comparison of FIB-4 index and aspartate aminotransferase to platelet ratio index on carcinogenesis in chronic hepatitis B treated with entecavir. J Cancer 2017;8(2):152-61.

27. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346(16):1221-31.

28. Haga Y, Kanda T, Sasaki R, Nakamura M, Nakamoto S, Yokosuka O. Nonalcoholic fatty liver disease and hepatic cirrhosis: comparison with viral hepatitis-associated steatosis. World J Gastroenterol 2015;21(46):12989-95.

29. Zhang Z, Wang G, Kang K, Wu G, Wang P. Diagnostic accuracy and clinical utility of a new noninvasive index for hepatic steatosis in patients with hepatitis B virus infection. Sci Rep 2016;6(1):32875.

30. Kahl S, Straßburger K, Nowotny B, Livingstone R, Klüppelholz B, Keßel K, et al. Comparison of liver fat indices for the diagnosis of hepatic steatosis and insulin resistance. PLoS One 2014;9(4):e94059.

31. Chang Y, Jung HS, Yun KE, Cho J, Cho YK, Ryu S. Cohort study of non-alcoholic fatty liver disease, NAFLD fibrosis score, and the risk of incident diabetes in a Korean population. Am J Gastroenterol 2013;108(12):1861-8.

32. Ju DY, Choe YG, Cho YK, Shin DS, Yoo SH, Yim SH, et al. The influence of waist circumference on insulin resistance and nonalcoholic fatty liver disease in apparently healthy Korean adults. Clin Mol Hepatol 2013;19(2):140-7.

33. Huh JH, Lee KJ, Lim JS, Lee MY, Park HJ, Kim MY, et al. High dietary sodium intake assessed by estimated 24-h urinary sodium excretion is associated with NAFLD and hepatic fibrosis. PLoS One 2015;10(11):e0143222.

34. Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. J Gastroenterol Hepatol 2011;26(9):e364-7.